- Home
- KLRS vs BEAT Comparison
KLRS vs BEAT Comparison
Compare KLRS & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KLRS | BEAT |
|---|---|---|
| Founded | 2019 | 2015 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.0M | 49.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | KLRS | BEAT |
|---|---|---|
| Price | $8.19 | $1.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $20.67 | $6.75 |
| AVG Volume (30 Days) | 52.8K | ★ 632.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.14 | $0.54 |
| 52 Week High | $12.90 | $4.00 |
Technical Indicators
Market Signals| Indicator | KLRS | BEAT |
|---|---|---|
| Relative Strength Index (RSI) | 42.30 | 39.36 |
| Support Level | $8.25 | $1.29 |
| Resistance Level | $10.28 | $1.47 |
| Average True Range (ATR) | 0.87 | 0.12 |
| MACD | -0.12 | -0.00 |
| Stochastic Oscillator | 5.00 | 29.31 |
Price Performance
Historical ComparisonAbout KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.